ライフサイエンスコーパス: virus-like particle

1 e short glycan displayed at the surface of a virus-like particle.

2 d domains of which can oligomerize to form a virus-like particle.

3 a virus Ankara (MVA) expressing HIV-1 Env on virus-like particles.

4 formation of Env on the surface of cells and virus-like particles.

5 orbornene (PNB) when attached to icosahedral virus-like particles.

6 even while it antagonizes the entrapment of virus-like particles.

7 performed shotgun metagenomic sequencing of virus-like particles.

8 MVA expressing noninfectious SIV macaque 239 virus-like particles.

9 ncy as well as different morphology lines of virus-like particles.

10 r HRV 2/4/6 virus-like particles but not 2/6 virus-like particles.

11 embrane are similar to the known contacts in virus-like particles.

12 site and severely impair RNA packaging into virus-like particles.

13 on of this dimer is essential for budding of virus-like particles.

14 filament formation and a lack of budding of virus-like particles.

15 that GP may enhance BST2 incorporation into virus-like particles.

16 e of plasma membrane PS in assembly of Ebola virus-like particles.

17 ic strength DeltaGag assembles into immature virus-like particles.

18 tein Gag co-opts this process for budding of virus-like particles.

19 ture of VP40 matrix layers within viruses or virus-like particles.

20 s prior to and during in vitro assembly into virus-like particles.

21 cteria provide the predominant population of virus-like particles.

22 ddition of glycans and/or multimerization on virus-like particles.

23 Here, influenza virus-like particles(4) carrying wild-type haemagglutini

24 ry protein, a noncovalent protein complex, a virus-like particle, a polymer, and a liposome sample, w

25 ere we analyzed two metagenomes derived from virus-like particles, analyzed the prevalence of the ide

26 lizing antibodies, N90-VRC38.01-11, by using virus-like particles and conformationally stabilized Env

27 ts, we examine HIV-1 Gag-mediated budding of virus-like particles and find that depleting Vps4 traps

28 ctions of Mxra8 bound to chikungunya (CHIKV) virus-like particles and infectious virus.

29 defective proviruses may form extracellular virus-like particles and may trigger immune responses.

30 Ty1 Gag comprises the capsid of virus-like particles and provides nucleic acid chaperone

31 domain greatly affect the production of both virus-like particles and replicon particles.

32 le-chain antibody HJT-R3-A9 to identify both virus-like particles and virus-containing fecal samples.

33 and the following binding partners: PS, EBOV virus-like particle, and EBOV glycoprotein/vesicular sto

34 ntisera from horses hyperimmunized with EBOV virus-like particles, and tested the post-exposure effic

35 , we determined structures of Qbeta virions, virus-like particles, and the Qbeta-MurA complex using s

36 sfected cell cultures, minireplicon systems, virus-like particles, and virus infections, we determine

37 ola and Marburg VP40 matrix layers in intact virus-like particles, and within intact Marburg viruses.

38 Additionally, budding and release of virus-like particles are prevented in M mutants that fai

39 Here we show that virus-like particles are relatively less abundant at hig

40 Due to the absence of viral genes, the virus-like particles are unable to spread or cause disea

41 Viromes derived from virus-like particles are unique to each individual, are

42 cts of intratumoral (IT) delivery of a novel virus-like particle as a lymphoma immunotherapy were eva

43 o have implications for the potential use of virus-like particles as protein delivery tools.

44 ynthetic or natural polymers, liposomes, and virus-like particles as well as nonbiodegradable NPs lik

45 Further, virus-like particle assays demonstrated that HRTV glycop

46 egment of a related phlebovirus, and we used virus-like particle assays to assess whether viral glyco

47 we report the crystal structure of an Orsay virus-like particle assembled from recombinant capsid pr

48 gene of the yeast Ty1 element that disrupts virus-like particle assembly in a dose-dependent manner.

49 nt protein was efficiently incorporated into virus-like particles at elevated temperature, the progen

50 antibodies were measured at baseline using a virus-like particle-based ELISA assay.

51 PV-18 immunoglobulin G (IgG) levels by an L1 virus-like particle-based enzyme-linked immunosorbent as

52 Immunogenicity was measured using a virus-like particle-based enzyme-linked immunosorbent as

53 or HPV antibodies (4 types) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme

54 With the goal of developing a virus-like particle-based vaccine based on dense bodies

55 herapy have also emerged, such as the use of virus-like particles, biologics or novel adjuvants.

56 NA followed by boosting with Kunjin replicon virus-like particles both encoding a modified Ebola glyc

57 but not LGG to Wa HRV particles or HRV 2/4/6 virus-like particles but not 2/6 virus-like particles.

58 mising clathrin-dependent internalization of virus-like particles by DC-SIGN.

59 The immature virus-like particles can be converted into mature capsid

60 ric and trimeric complexes are on pathway to virus-like particle (capsid) formation.

61 rmined the cryo-EM structures of chikungunya virus-like particles complexed with antibody fragments (

62 CMP-001 is a virus-like particle composed of the Qbeta bacteriophage

63 Env-specific B cells after immunization with virus-like particles containing GagPol and Env.

64 oneedle (MN) patch for skin vaccination with virus-like particles containing influenza virus heterolo

65 assembly is partially restored, although the virus-like particles created are incomplete, implying th

66 rated with influenza HA-antigens in chimeric virus-like particles (cVLPs), in boosting strong protect

67 d-based nanoparticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus macr

68 cine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic vir

69 ied vaccinia Ankara (MVA) vaccines producing virus-like particles displaying trimeric membrane-bound

70 Similarly, upon vaccination with virus-like particles displaying vesicular stomatitis vir

71 large amounts of penton-dodecahedra (PtDd), virus-like particles, during replication.

72 , this masking does not explain the observed virus-like particle egress enhancement.

73 RNA-free virus-like particles (empty virus-like particles [eVLPs]

74 efficient approach for production of stable virus-like particles encapsidating nonnative RNAs or oth

75 e Gag is sufficient to drive the assembly of virus-like particles even in the absence of gRNA binding

76 plant virus Cowpea Mosaic virus (CPMV) empty virus like particles (eVLPs).

77 RNA-free virus-like particles (empty virus-like particles [eVLPs]) can be generated by transi

78 the cleaved Env on the surface of cells and virus-like particles exhibits an antigenic profile consi

79 infecting mosquitoes and a vaccine based on virus-like particles expressing envelope proteins.

80 DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durab

81 rotein nanoparticles, such as viral capsids, virus-like particles, ferritin, heat-shock proteins and

82 during inflammation, and conjugated them to virus-like particles, followed by immunization of mice.

83 ng that the kinetics of self-assembly of our virus-like particles follows a previous model developed

84 tein nanocontainers for drug delivery and of virus-like particles for vaccination.

85 NP adjuvants mixed with soluble SIV Env or a virus-like particle form of Env (VLP) induces potent and

86 We extracted virus-like particles from 89 patients with AH who were e

87 Analysis of virus-like particles from a filtrate found to reduce sym

88 bservational study, we extracted RNA and DNA virus-like particles from fecal samples from 73 patients

89 Virus-like particles from fecal samples were fractionate

90 nd immunotherapy, and inactivated viruses or virus-like particles have long been used as vaccines.

91 als of vaccines consisting of nonreplicating virus-like particles have shown promise.

92 Importantly, high-Env virus-like particles (hVLPs) were produced with a manife

93 Structures of chikungunya virus-like particles in complex with strongly neutralizi

94 ntibodies elicited by immunization via Pfs25 virus-like particles in human immunoglobulin loci transg

95 combinant FMDV subunit antigens and produced virus-like particles in mammalian and bacterial cells.

96 (1,2)fucosylated motifs and binding of GII.4 virus-like particles in nonsecretors' mucosa were associ

97 From its ability to assemble into virus-like particles in vitro, we infer that RSV Gag is

98 er, how VP40 interacts with the PM and forms virus-like particles is for the most part unknown.

99 e to code for all viral proteins and produce virus-like particles, it is not known if these virus par

100 V vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprote

101 titution, were efficiently incorporated into virus-like particles lacking infectivity.

102 Moloney murine leukemia virus-like particles (M-VLPs) were complexed with chitos

103 Non-infectious murine leukemia virus-like particles (M-VLPs) were electrostatically com

104 s have been used to study Gag expression and virus-like particle morphology among representative retr

105 t these limitations, we used enzymatic Nipah virus-like-particles (NiVLPs) and developed new flow vir

106 the authors use plants to express stabilized virus-like particles of type 3 poliovirus that can induc

107 rmed on assemblies (P dimer, P particle, and virus-like particle) of recombinant viral capsid protein

108 ants and carriers, as well as those based on virus-like particles offer several key advantages to hel

109 different norovirus genotypes as recombinant virus-like particles or in clinical samples was dependen

110 r proteasomal degradation using specialized, virus-like particles-potentiates the cytotoxicity of Ara

111 Similar results are obtained with virus-like particles produced with SARS-CoV-2 M, N, E, a

112 We show that our virus-like particles protect DNA against enzymatic degra

113 Fluorescent staining of virus-like particles purified from infant meconium or ea

114 mRNA LNPs encoding prM-E genes that produced virus-like particles resulted in high neutralizing antib

115 le-chain variable fragment complexed with BK virus-like particles revealed the quaternary nature of a

116 nt correlation between the level of in vitro virus-like particle secretion, the elicited antibody res

117 Hepatitis E Virus-like particles self-assemble in to noninfectious n

118 d compared the results with prM/E containing virus-like particle-specific MAC-ELISA (VLP-MAC-ELISA).

119 d alone, VP40 induces budding of filamentous virus-like particles, suggesting that localization to th

120 were recognized by murine antisera to HPV58 virus-like particles, suggesting that these are antibody

121 veloping a synthetically produced stabilized virus-like particle (sVLP)-based vaccine with D antigeni

122 ce TLR2 ligation was defined using synthetic virus-like particles (SVLPs) carrying hydrophobic TLR2 P

123 tablishment of a transcriptionally competent virus-like particle (tc-VLP) system for CCHFV.

124 signed DIs as fully encapsidated, infectious virus-like particles termed defective interfering partic

125 96)-Pol-Nef(CN54) polyprotein as Gag-derived virus-like particles (termed NYVAC-C-KC).

126 ural empty particle, and a recombinant CVA16 virus-like particle that does not contain the viral geno

127 P40 in mammalian cells is sufficient to form virus-like particles that are nearly indistinguishable f

128 , viruses are often accompanied by defective virus-like particles that carry large deletions in their

129 cement of liposomes with bacteriophage Qbeta virus-like particles that displayed the same self-antige

130 ly, by comparing the Qbeta virion with Qbeta virus-like particles that lack a maturation protein, we

131 Using canine norovirus virus-like particles, this work shows that representativ

132 nd the biosensing efficacy of Tobacco mosaic virus-like particle (TMV VLP) sensing probes using an im

133 uctions for the wild-type virus and an empty virus-like particle, to 3.4 A and 3.0 A resolution, resp

134 A cholesterol-dependent virus-like particle trap assay, based on co-expression o

135 and transcription- and replication-competent virus-like particle (trVLP) systems, allow modeling of t

136 rotavirus double-layered particles and HIV-1 virus-like particles under low-dose conditions (5.7 e/ a

137 We tested a virus-like particle vaccine against Ebola virus, a leadi

138 dults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demons

139 g disease after intranasal immunization with virus-like particle vaccine containing the RSV fusion pr

140 m clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possi

141 To mimic the human condition, COBRA HA virus-like particle vaccines were tested in ferrets that

142 We developed a potential Virus Like Particle (VLP) based multivalent vaccine cand

143 We have devised a virus like particle (VLP) carrier based on the hepatitis

144 ain protection provided by a multivalent NoV virus-like particle (VLP) candidate vaccine in human vol

145 e-escalation, open-label clinical trial of a virus-like particle (VLP) chikungunya virus vaccine, VRC

146 tron microscopy (cryo-EM) structure of a B19 virus-like particle (VLP) complexed with the antigen-bin

147 Virus-like particle (VLP) conjugates are being developed

148 IL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell

149 consisted of eIL-31 covalently coupled to a virus-like particle (VLP) derived from cucumber mosaic v

150 ial vaccine utilizing the AP205 capsid-based virus-like particle (VLP) designed to simultaneously dis

151 In this study, we report a virus-like particle (VLP) for building a 3D plasmonic na

152 ns were developed and tested in mice using a virus-like particle (VLP) format for the elicitation of

153 of bivalent synbody affinity ligands using a virus-like particle (VLP) from the 2006 GII.4 Minerva st

154 ited following vaccination or preclinical L1 virus-like particle (VLP) immunization or by monoclonal

155 hly protective CSP-based P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide

156 is study, we constructed a bivalent chimeric virus-like particle (VLP) presenting the VP1 (aa208-222)

157 sing an in-house-generated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we valida

158 tential applications in the development of a virus-like particle (VLP) vaccine as well as small-molec

159 with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted w

160 We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations

161 phase 2 trial of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate in 50 health

162 human maternal immunization, with novel RSV virus-like particle (VLP) vaccine candidates containing

163 development and evaluation of a Pfs47-based virus-like particle (VLP) vaccine generated by conjugati

164 to efficiently separate the nanoparticle and virus-like particle (VLP) vaccine molecules from host ce

165 To overcome this, we used a virus-like particle (VLP) vaccine platform (PP7) for con

166 e development of a bivalent, spherical Ebola virus-like particle (VLP) vaccine that incorporates glyc

167 hus may be more economically viable than the virus-like particle (VLP) vaccine.

168 Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current

169 L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe,

170 Vaccinating ferrets with virus-like particle (VLP) vaccines expressing COBRA HA p

171 istorical H3N2 viruses, were vaccinated with virus-like particle (VLP) vaccines expressing either an

172 ssed by the production and use of virus-free virus-like particle (VLP) vaccines that mimic the "empty

173 Among the potential anti-hRSV approaches are virus-like particle (VLP) vaccines, which, based on rese

174 RSV F virus-like particle (VLP) would be an efficient vaccine

175 We previously compared five different virus-like particle (VLP)-associated, mutation-stabilize

176 We used a virus-like particle (VLP)-based approach to develop a va

177 r intramuscular administration of 2 bivalent virus-like particle (VLP)-based candidate norovirus vacc

178 tion, we tested the hypothesis that chimeric virus-like particle (VLP)-based vaccine platforms, which

179 Here, we developed ZIKV subunit- and virus-like particle (VLP)-based vaccines displaying E in

180 nt of efficacious vaccines, human trials for virus-like particle (VLP)-based vaccines show promise in

181 comprises up to 90% and 22% of all reads in virus-like particle (VLP)-derived metagenomes and total

182 domain of matrix protein 2 (M2e) fused to a virus-like particle (VLP).

183 in that appears to be in the interior of the virus-like particle (VLP).

184 rotein (sE-cvD), the other is a more complex virus-like particle (VLP-cvD).

185 were examined in combination with influenza virus-like particles (VLP) (M8-VLP) expressing H5N1 infl

186 accines consist of major capsid protein (L1) virus-like particles (VLP) and are highly efficacious ag

187 d inflammatory gene networks using influenza virus-like particles (VLP) expressing HA and NA as immun

188 We used virus-like particles (VLP) to study the effect of acylat

189 responses to RSV F and G protein-containing virus-like particles (VLP), comparing responses to those

190 med HPV-07, was selected to bind the Type 16 virus-like-particle (VLP) formed by the self-assembling

191 lles, dendrimers, liposomes, polyplexes, and virus-like-particles (VLP), as well as therapeutic relev

192 HIV-1 immature particle (virus-like particle [VLP]) assembly is mediated largely

193 e demonstrate that non-infectious SARS-CoV-2 virus like particles (VLPs) can be assembled by co-expre

194 Virus like particles (VLPs) of P22 containing ziconotide

195 infectious particles and their corresponding virus like particles (VLPs).

196 via display on multimerisation scaffolds or virus like particles (VLPs).

197 and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and

198 ated for 50% blocking titer (BT50) values of virus-like particles (VLPs) against pig gastric mucin (P

199 p22/p18 cofractionates with Ty1 virus-like particles (VLPs) and affects VLP yield, prote

200 , we developed a panel of four GII.2 variant virus-like particles (VLPs) and compared their antigenic

201 al for positively regulating egress of eVP40 virus-like particles (VLPs) and for egress and spread of

202 sed to assess the binding specificity of CNV virus-like particles (VLPs) and identified alpha1,2-fuco

203 accine directs the synthesis and assembly of virus-like particles (VLPs) and induces immune responses

204 facilitate efficient release of VP40-driven virus-like particles (VLPs) and infectious virus.

205 the spontaneous interaction between HPV16 L1 virus-like particles (VLPs) and non-functionalized GNPs

206 used for the production of prM/E-containing virus-like particles (VLPs) and secreted NS1 (sNS1) from

207 d by using both noninfectious wild-type (wt) virus-like particles (VLPs) and soluble nonstructural pr

208 lution, two calibration standards were used: Virus-Like Particles (VLPs) and synthetic beads with a m

209 graphy (cryo-ET) to directly visualize HIV-1 virus-like particles (VLPs) and virions tethered to huma

210 Assembly of HIV-1 Gag into virus-like particles (VLPs) appears to require an intera

211 NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant.

212 Virus-like particles (VLPs) are an attractive alternativ

213 Virus-like particles (VLPs) are an attractive vaccine ca

214 Virus-like particles (VLPs) are an attractive vaccine ca

215 Virus-like particles (VLPs) are attractive as a vaccine

216 Virus-like particles (VLPs) are ideal platforms for such

217 Virus-like particles (VLPs) are important vaccine platfo

218 Virus-like particles (VLPs) are non-infectious self-asse

219 Virus-like particles (VLPs) are stable protein cages der

220 uence and incorporated into Env-enriched HIV virus-like particles (VLPs) as a molecular adjuvant.

221 infection is essential when using viruses or virus-like particles (VLPs) as an immunotherapeutic agen

222 PxY-dependent budding of Marburg (MARV) VP40 virus-like particles (VLPs) as our model system, we iden

223 ession impair production and release of EBOV virus-like particles (VLPs) as well as infectivity of GP

224 electron microscopy, we demonstrate that HIV virus-like particles (VLPs) assembled by the viral prote

225 f that trigger sequence-specific assembly of virus-like particles (VLPs) at much higher fidelity and

226 Virus-like particles (VLPs) built on the Newcastle disea

227 xpression of VP40 leads to the production of virus-like particles (VLPs) by a mechanism that accurate

228 Virus-like particles (VLPs) can be used as nano-carriers

229 owed that seven different genotypes of HuNoV virus-like particles (VLPs) can bind to canine gastroint

230 rt here the high-resolution structure of B19 virus-like particles (VLPs) complexed with the Fab of a

231 ed or sterically hindered N termini, such as virus-like particles (VLPs) composed of the well-studied

232 pe (Env) gp140 and Gag p55 (protein) or with virus-like particles (VLPs) containing SIVmac239 Env and

233 Recombinantly expressed virus-like particles (VLPs) could address these inherent

234 he successful assembly of nuclease-resistant virus-like particles (VLPs) depends delicately on the st

235 mmature lattice in noncrystalline, spherical virus-like particles (VLPs) derived from Gag.

236 (M), and protein immunogens, all expressing virus-like particles (VLPs) displaying membrane-anchored

237 Z-Tsg101 interaction and inhibits budding of virus-like particles (VLPs) driven by ectopic expression

238 Mice were vaccinated with virus-like particles (VLPs) expressing one of the 12 mod

239 ixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filoviru

240 antigens gp140, and Gag/Gag-Pol-Nef-derived virus-like particles (VLPs) from clade C and were used a

241 We purified virus-like particles (VLPs) from ddm1 and ddm1rdr6 mutan

242 ns from SARS-CoV-2 for their ability to form virus-like particles (VLPs) from human cells to form a c

243 Virus-like particles (VLPs) have become a promising plat

244 Virus-like particles (VLPs) have been extensively explor

245 retrotransposons Ty1 and Ty3, which assemble virus-like particles (VLPs) in intracytoplasmic ribonucl

246 also contributes to efficient production of virus-like particles (VLPs) in transfected cells.

247 Spiked virus-like particles (VLPs) in wasp venom have clearly b

248 MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB activation

249 ng epitopes in human papillomavirus (HPV) L1 virus-like particles (VLPs) is the structural basis of p

250 lergen, displayed in a repetitive fashion on virus-like particles (VLPs) may fulfill these criteria.

251 t cells and were shown to self-assemble into virus-like particles (VLPs) morphologically similar to t

252 HIV-1, we performed comparative analyses of virus-like particles (VLPs) obtained by expression of wi

253 licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid prote

254 he three currently licensed vaccines contain virus-like particles (VLPs) of the L1 major capsid prote

255 Here we show the structure of MrNV virus-like particles (VLPs) produced by recombinant expr

256 eries metagenomic study of DNA isolated from virus-like particles (VLPs) recovered from fecal samples

257 Antigenicity of virus-like particles (VLPs) representative of clusters I

258 Hyperimmune sera raised against virus-like particles (VLPs) representing different genot

259 f VP40 leads to the production and egress of virus-like particles (VLPs) that accurately mimic the bu

260 uced by rNDVs was able to self-assemble into virus-like particles (VLPs) that are morphologically sim

261 coexpression led to coordinated assembly of virus-like particles (VLPs) that were morphologically an

262 d have assessed the ability of the resulting virus-like particles (VLPs) to encapsidate mutant STNV-1

263 Here we used phage display against virus-like particles (VLPs) to isolate seven human monoc

264 teraction kinetics and the affinity of HuNoV virus-like particles (VLPs) to lipid vesicles produced f

265 rm exclusively T = 2-sized (~22-nm diameter) virus-like particles (VLPs) when mixed with cowpea chlor

266 ells results in the formation and budding of virus-like particles (VLPs) which mimic the budding proc

267 Virus-like particles (VLPs) with increased density of En

268 irus (CCMV), we demonstrate the synthesis of virus-like particles (VLPs) with one end of the packaged

269 so required for the production of infectious virus-like particles (VLPs), and that defective VLPs wit

270 Virus-like particles (VLPs), comprised of viral structur

271 e 3.89- angstrom structure of the M. spretus virus-like particles (VLPs), determined using cryo-elect

272 -state NMR (ssNMR) measurements on spherical virus-like particles (VLPs), facilitated by segmental is

273 r of IBV E is required for the production of virus-like particles (VLPs), implicating this form of th

274 CpGs into nanoparticles, in particular into virus-like particles (VLPs), improves the pharmacologica

275 ly restricted by REAF and, using delivery by virus-like particles (VLPs), that Vpr alone is sufficien

276 capsomers, obtained from the disassembly of virus-like particles (VLPs), were incubated with nuclear

277 ave previously established a system based on virus-like particles (VLPs), which allows tracking of VL

278 a novel tetravalent dengue vaccine by using virus-like particles (VLPs), which are noninfectious bec

279 a novel RNAi scaffold, packaged within Qbeta virus-like particles (VLPs).

280 ein (G) autonomously induce the formation of virus-like particles (VLPs).

281 ovel tetravalent dengue vaccine by utilizing virus-like particles (VLPs).

282 -meric E2p that displays 20 spikes mimicking virus-like particles (VLPs).

283 valent prophylactic HPV vaccines composed of virus-like particles (VLPs).

284 on with virus or immunization with influenza virus-like particles (VLPs).

285 lone is usually sufficient for production of virus-like particles (VLPs).

286 mulation of L1-dsRNA/SsMBV1 and stability of virus-like particles (VLPs).

287 tion to an extended rod-like conformation in virus-like particles (VLPs).

288 nt network within tobacco mosaic virus (TMV) virus-like particles (VLPs).

289 teins can assemble in vitro to form immature virus-like particles (VLPs).

290 .7, and GI.1 human norovirus outbreak strain virus-like particles (VLPs).

291 acids (NAs), it spontaneously assembles into virus-like particles (VLPs).

292 CDots) antiviral activity to human norovirus virus-like-particles (VLPs), GI.1 and GII.4 VLPs.

293 from CCR5 at high density on the surface of virus-like particles, we can efficiently induce high-tit

294 With this knowledge, and using virus-like particles, we could demonstrate that the last

295 Virus-like particles were stained to confirm the presenc

296 as that of genogroup I.1 and genogroup II.4 virus-like particles, were compared in a series of 109 d

297 versatile woodchuck hepadnavirus core-based virus-like particle (WHcAg-VLP) to generate hybrid VLPs

298 ral capsid proteins, several of which formed virus-like particles when expressed in culture.

299 y digesting immature particles and assembled virus-like particles with recombinant HIV-1 protease and

300 developed a plasmid-based system to produce virus-like particles with the ability to infect cells an